Journal of Oncology / 2019 / Article / Tab 1

Research Article

Oncosuppressive Role of RUNX3 in Human Astrocytomas

Table 1

Associations between grade I-IV astrocytoma patients’ clinical data and RUNX3 gene molecular properties.

Methylation Protein expression
VariableUnmethylated % (n)Methylated 
% (n)

(χ2; df)
Low 
% (n)
High 
% (n)

Overall67.6 (92)32.4 (44)48.6 (35)51.4 (37)

Grade
 I100 (14)0 (0)<0.001
(49.3; 3)
66.7 (4)33.3 (2)0.007
 II88.6 (39)11.4 (5)25.9 (7)74.1 (20)
 III82.8 (24)17.2 (5)35.3 (6)64.7 (11)
 IV (GBM)30.6 (15)69.4 (34)81.8 (18)18.2 (4)

Gender
 Male65.6 (40)34.4 (21)0.641 
(0.22; 1)
48.8 (20)51.2 (21)0.707
 Female69.3 (52)30.7 (23)48.4 (15)51.6 (16)

Age, years
 <5088.7 (63)11.3 (8)<0.001
(30.2; 1))
32.5 (13)67.5 (27)0.037
 ≥5044.6 (29)55.4 (36)68.8 (22)31.2 (10)

Survival, months
 <2440 (22)60 (33)<0.001
(32.2; 1)
80 (20)20 (5)0.001
 ≥2486.4 (70)13.6 (11)31.9 (15)68.1 (32)

Methylation
 Unmethylated39.2 (20)60.8 (31)0.026
 Methylated68.4 (13)31.6 (6)

P-value estimated by Pearson Chi-square (χ2) test.
Kruskal-Wallis test.
Mann-Whitney U test.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.